The estimated Net Worth of Robert Bindert Huizinga is at least $6.59 Million dollars as of 2 March 2022. Mr. Huizinga owns over 4,849 units of Aurinia Pharmaceuticals Inc stock worth over $453,045 and over the last 4 years he sold AUPH stock worth over $5,484,286. In addition, he makes $647,803 as Executive Vice President - Corporate Development at Aurinia Pharmaceuticals Inc.
Sign up
Mr. Huizinga AUPH stock SEC Form 4 insiders trading
Robert has made over 6 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 4,849 units of AUPH stock worth $58,236 on 2 March 2022.
The largest trade he's ever made was selling 130,000 units of Aurinia Pharmaceuticals Inc stock on 25 October 2021 worth over $3,867,500. On average, Robert trades about 40,808 units every 49 days since 2021. As of 2 March 2022 he still owns at least 69,379 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Huizinga stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Huizinga biography
Dr. Robert B. Huizinga serves as Executive Vice President - Corporate Development of the Company.D. serves as Executive Vice President - Corporate Development of the Company. Mr. Huizinga has been with the Company since 2002, focused on managing the global clinical development of voclosporin. Before joining the Company, Mr. Huizinga was a Nephrology and Transplantation nursing specialist with 14 years of clinical and research experience where he was involved in more than 60 clinical trials from Phase I through Phase IV. He has acted as a consultant to nephrology and transplantation pharmaceutical companies, and has lectured extensively. Mr. Huizinga holds a M.Sc. in medicine (epidemiology) from the University of Alberta, is a registered nurse, certified in nephrology, and a member of Sigma Theta Tau (Honor Society of Nursing).
What is the salary of Robert Huizinga?
As the Executive Vice President - Corporate Development of Aurinia Pharmaceuticals Inc, the total compensation of Robert Huizinga at Aurinia Pharmaceuticals Inc is $647,803. There are 5 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
What's Robert Huizinga's mailing address?
Robert's mailing address filed with the SEC is #1203-4464 MARKHAM STREET, , VICTORIA, A1, V8Z7X8.
Insiders trading at Aurinia Pharmaceuticals Inc
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, and Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
What does Aurinia Pharmaceuticals Inc do?
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
What does Aurinia Pharmaceuticals Inc's logo look like?
Complete history of Mr. Huizinga stock trades at Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc executives and stock owners
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Peter Greenleaf,
President, Chief Executive Officer, Director -
Peter S. Greenleaf M.B.A.,
Pres, CEO & Director -
Maxwell Donley,
Executive Vice President, Internal Operations & Strategy -
Neil Solomons,
Chief Marketing Officer -
Massimiliano Colao,
Chief Commercial Officer -
Robert Huizinga,
Executive Vice President - Corporate Development -
Matthew Maxwell Donley M.B.A.,
Exec. VP of Operations & Strategy -
Joseph M. Miller CPA,
Chief Financial Officer -
Dennis Bourgeault,
Chief Financial Officer -
Michael Martin,
Chief Operating Officer -
Daniel Billen,
Director -
George Milne,
Independent Chairman of the Board -
Michael Hayden,
Independent Director -
Stephen P. Robertson,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Joseph Hagan,
Independent Director -
David Jayne,
Independent Director -
R. Hector MacKay-Dunn,
Director -
Jill Leversage,
Independent Director -
Stephen Robertson,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Timothy Walbert,
Independent Director -
Max Colao,
Chief Commercial Officer -
Tim Hermes,
Vice President of Market Access -
Cara Felish,
Vice President of Commercial Operations -
Chris Hays,
Vice President of Marketing -
Fran Lynch,
Vice President of Sales -
Glenn Schulman,
Senior Vice President - Corporate Communications and Investor Relations -
Michael R. Martin,
Chief Bus. Officer -
Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
Exec. VP of Research -
Scott Michael Habig,
Chief Commercial Officer -
Volker Knappertz,
EVP, Research and Development -
Joseph M Miller,
Chief Financial Officer -
Brinda Balakrishnan,
Director -
Robert T Foster,
Director -
Massimilano Colao,
Chief Commercial Officer -
Jeffrey Allen Bailey,
Director -
Karen L. Smith,
Director